Vinay Prasad, a top official at the Food and Drug Administration, has suddenly departed after a series of controversial decisions about a treatment for boys with Duchenne muscular dystrophy.
“Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,” Health and Human Services Department spokesperson Andrew Nixon told STAT. “We thank him for his service and the many important reforms he was able to achieve in his time at FDA.”
Prasad was the head of the Food and Drug Administration division that regulates vaccines, gene therapies, and blood products. He was also the agency’s chief medical and scientific officer, making him a top adviser to Commissioner Marty Makary. Prasad didn’t immediately respond to requests for comment.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
